3Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone:differences in interactions with hydroxyapatite [J]. Bone,2006 ;38:617-27.
4Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates [J]. J Pharmacol Exp Ther,2001 ;296:235-42.
5Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[J]. N Engl J Med,2007 ;356 : 1809-22.
7Saag K, Geusens P. Progress in osteoporosis and fractureprevention :focus on postmenopausal women. Arthritis Res Ther,2009,11:251-256.
8Wellington K,Wagstaff AJ. Tranexamic acid : a review of its usein the management of menorrhagia. Drugs, 2003 ,63 (13):1417-1433.
9McClung M , Miller P, Recknor C , et al. Zoledronic acid for theprevention of bone loss in postmenopausal women with low bonemass : a randomized controlled trial. Obstet Gynecol, 2009 , 114.5) :999-1007.
10Boonen S, Black DM,Colon-Emetic CS, et al. Efficacy and safetyof a once-yearly intravenous zoledronic acid 5 mg for fractureprevention in elderly postmenopausal woman with osteoporosisaged 75 and older. J Am Gedatr Soc,2010 ,58(2) : 292 ,299.
